Provided by Tiger Trade Technology Pte. Ltd.

CorMedix Inc.

8.28
+0.08000.98%
Post-market: 8.360.0800+0.97%19:30 EDT
Volume:1.01M
Turnover:8.43M
Market Cap:645.38M
PE:3.97
High:8.50
Open:8.28
Low:8.18
Close:8.20
52wk High:14.96
52wk Low:6.13
Shares:77.94M
Float Shares:66.02M
Volume Ratio:0.62
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.08
EPS(LYR):2.04
ROE:54.93%
ROA:24.56%
PB:1.40
PE(LYR):4.06

Loading ...

CorMedix Q1 Basic EPS USD 0.48

THOMSON REUTERS
·
May 14

CorMedix Inc expected to post earnings of 36 cents a share - Earnings Preview

Reuters
·
May 12

CorMedix to report Q1 results, host corporate update call

Reuters
·
May 05

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

THOMSON REUTERS
·
May 05

Citizens healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Apr 29

CorMedix Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 28

RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Apr 28

Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD) and Relay Therapeutics (RLAY)

TIPRANKS
·
Apr 28

CorMedix Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 27

BRIEF-Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial

Reuters
·
Apr 27

CorMedix says Phase III ReSPECT trial meets primary endpoint for REZZAYO prophylaxis

Reuters
·
Apr 27

CorMedix Inc - Companies Anticipate Pre-Nda Meeting With FDA, Target Snda Submission in 2H26

THOMSON REUTERS
·
Apr 27

CorMedix Inc - Study Shows Favorable Benefit for Toxicity Related Discontinuations and Drug-Drug Interactions

THOMSON REUTERS
·
Apr 27

CorMedix Inc - Rezafungin Well Tolerated With Safety Profile Comparable to Standard Regimens

THOMSON REUTERS
·
Apr 27

CorMedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial Assessing Rezzayo® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

THOMSON REUTERS
·
Apr 27

CorMedix Inc - Respect Study Meets Primary Endpoint for Fungal-Free Survival at Day 90

THOMSON REUTERS
·
Apr 27

RBC Capital Sticks to Its Buy Rating for Cormedix (CRMD)

TIPRANKS
·
Apr 09

CorMedix to join Needham Virtual Healthcare Conference fireside chat and investor meetings

Reuters
·
Apr 07

CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

TIPRANKS
·
Mar 07

CorMedix price target lowered to $13 from $15 at Leerink

TIPRANKS
·
Mar 07